21 min ago | Philly.com
Ex-Synthes CEO gives $125M to Harvard
Atlantic City's $2.4 billion Revel casino formally completed its financial restructuring and emerged from Chapter 11 bankruptcy Tuesday.
DePuy Announces It Will Stop Selling Metal-On-Metal Hip Implants, Notes Rottenstein Law Group LLP
The firm is actively filing DePuy ASR lawsuits on behalf of those who allegedly suffered metallosis, premature device failure, or other serious complications related to the 2010 DePuy ASR recall.
A friend went into a kids hair salon and was asking about shampoo. The beautician said that there was a recent show on 20/20 or etc.
Johnson & Johnson's Short-Term Pipeline
You will find a comprehensive dividend stock analysis of Johnson & Johnson in this article .
How Dividends Change the Game for Johnson & Johnson Stock
The single, easiest way to keep track of all the stocks that matter... Your own personalized stock watchlist! It's a 100% FREE Motley Fool service... The wealth-building power of compound interest will never cease to amaze me.
Janssen's Manufacturing Problems May Lead to Criminal Charges in Korea
Though Janssen Korea says it is confident it will resolve its manufacturing issues, product recall and suspensions could be followed by lawsuits and imprisonment.
Peterborough Staff Help Company Achieve 'Best In The World' Ranking
The study saw more than 400 patient groups from 39 different countries assessing 30 'medtech' companies on their ability to meet patient expectations.
Will Obamacare Crush Medtronic's Earnings?
The key to making smart investment decisions on stocks reporting earnings is to anticipate how they'll do before they announce results, leaving you fully prepared to respond quickly to whatever inevitable surprises arise.
Avon CEO to Address Stonehill College Graduates
Sheri S. McCoy, the chief executive officer and a director of Avon Products, will deliver the keynote address at Stonehill College's 62nd Commencement on Sunday, May 19.
Investment Ideas in the Expanding Wound Care Market
The wound care market may not be the most exciting biotech niche on the surface, but the multi-billion dollar industry's need for innovation has created an opportunity for smaller companies operating in the space.
Johnson & Johnson Outlines Poppy Supply Plans
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! Johnson and Johnson could be sourcing commercial quantities of poppies outside Tasmania in 2015.
Johnson & Johnson Ending Sales of Metal-on-Metal Hip Implants
Johnson & Johnson, the world's biggest maker of health-care products, said it will stop selling metal-on-metal and ceramic-on-metal hip replacements as demand wanes for the devices and U.S. regulators seek new rules.
Five lessons in corporate brand building from the big boys
Research by media monitoring company Precise, published in March 2013 says that consumers are more likely to view FMCG companies favourably if they develop a recognisable corporate brand.
EDANA, the Association Serving the Nonwovens and Related Industries, has announced its new board of governors for 2013-2015, the most international board ever the group says with representatives from across Europe, the Middle East, United States and Asia.
Retirement investors: Dividend or valued stocks?
With interest rates near zero, investors have been desperately seeking yield. As a result, one of the hottest trades for investors over the last three to four years has been buying large companies that pay high dividends.
Johnson & Johnson, Medtronic Frontrunners In Race To Develop Artificial Pancreas
A small implantable device, an artificial pancreas would continuously monitor blood-sugar levels and release insulin as needed in patients with Type 1 diabetics.
Johnson & Johnson: At The Crossroads - Part III
In Part I of "Johnson & Johnson: At The Crossroads", consideration was given to whether a dividend growth rate of 8.2% was sustainable if net income growth rate remained around the projected 6%. It was determined that this gap between dividend and net income growth rates was likely sustainable for at least the next 15 years.
JPMorgan - Why I'm All In With Jamie Dimon
After listening to the media trash JP Morgan's Jamie Dimon for the past year, and following the recent uproar caused by proxy firm recommendations that shareholders vote to separate the company's Chairman and CEO functions, I simply cannot sit by any longer without speaking up in Dimon's defense.
This app helps you avoid supporting Monsanto and other terrible companies
When shopping in any store that carries national brands, it's virtually impossible to remember which ones you're not supposed to buy for which reasons.
J&J Wins Expanded Approval of Simponi to Treat Bowel Disease
Johnson & Johnson won U.S. approval to use its rheumatoid arthritis drug Simponi to treat patients suffering from a moderate to severe inflammatory bowel disease.